We evaluated gene expression differences of these transcription repressors in AML patients and determined that HDAC2 gene expression was significantly higher, while GATAD2A was significantly lower in refractory AML patients compared to clinical-treatment-responsive patients. The gene discussed is GATAD2A; the disease is acute myeloid leukemia.